SCHEMBL3259183

SCHEMBL3259183

O=C(O)C1C[C@@H]2CC[C@H]1O2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
GMNN O75496 1/20 0.44
LMNA P02545 1/20 0.44
PMP22 Q01453 1/20 0.44
TFPI2 P48307 1/20 0.44
TP53 P04637 1/20 0.44
TSHR P16473 1/20 0.44
NFKB1 P19838 1/20 0.44
THPO P40225 1/20 0.44
RIPK1 Q13546 3/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
GABRR1 P24046 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
PPM1B O75688 1/20 0.34
PTPN1 P18031 1/20 0.34
PPP1CC P36873 1/20 0.34
PSMB8 P28062 1/20 0.33
PSMB5 P28074 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8239877 1.00 KDM4E (0.44) KDM4EGMNNLMNAPMP22TFPI2
SCHEMBL13795024 1.00 KDM4E (0.44) KDM4EGMNNLMNAPMP22TFPI2
SCHEMBL3465697 1.00 KDM4E (0.44) KDM4EGMNNLMNAPMP22TFPI2
SCHEMBL34461967 1.00 KDM4E (0.44) KDM4EGMNNLMNAPMP22TFPI2
SCHEMBL9376106 1.00 KDM4E (0.44) KDM4EGMNNLMNAPMP22TFPI2
SCHEMBL4738730 1.00 KDM4E (0.44) KDM4EGMNNLMNAPMP22TFPI2
SCHEMBL8246038 1.00 KDM4E (0.44) KDM4EGMNNLMNAPMP22TFPI2
SCHEMBL8067270 1.00 KDM4E (0.44) KDM4EGMNNLMNAPMP22TFPI2
SCHEMBL4738727 1.00 KDM4E (0.44) KDM4EGMNNLMNAPMP22TFPI2
SCHEMBL2969767 1.00 KDM4E (0.44) KDM4EGMNNLMNAPMP22TFPI2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10023587-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2018-07-17 US disclosed
US-20170369503-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2017-12-28 US disclosed
EP-2124550-B1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY INC (US) 2017-04-19 EP disclosed
US-9079917-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2015-07-14 US disclosed
US-9079917-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2015-07-14 US disclosed
US-20150045373-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. 2015-02-12 US disclosed
US-20150045373-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. 2015-02-12 US disclosed
US-8822461-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2014-09-02 US disclosed
US-8822461-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2014-09-02 US disclosed
US-20130302402-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2013-11-14 US disclosed
US-20130302402-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2013-11-14 US disclosed
US-8426444-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2013-04-23 US disclosed
US-8426444-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2013-04-23 US disclosed
US-20120270736-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2012-10-25 US disclosed
US-7998957-B2 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2011-08-16 US disclosed
EP-1937248-B1 ALCANOIC ACID AMIDES SUBSTITUTED BY SATURATED O-HETEROCYCLES NOVARTIS AG (CH) 2010-06-02 EP disclosed
US-20090275651-A1 Alcanoic Acid Amides Substituted by Saturated O-Heterocycles SPEEDEL EXPERIMENTA AG 2009-11-05 US disclosed
US-20090036309-A1 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. 2009-02-05 US disclosed
EP-1937248-A2 ALCANOIC ACID AMIDES SUBSTITUTED BY SATURATED O-HETEROCYCLES Speedel Experimenta AG (CH) 2008-07-02 EP disclosed
WO-2007031557-A2 ALCANOIC ACID AMIDES SUBSTITUTED BY SATURATED O-HETEROCYCLES SPEEDEL EXPERIMENTA AG (CH) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270736-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE HCCS, OXA1L, OTC KDM4E 1204/4885GMNN 908/4885LMNA 2628/4885
US-20150045373-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE HCCS, OXA1L, OTC KDM4E 1204/4885GMNN 908/4885LMNA 2628/4885
US-20130302402-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE HCCS, OXA1L, OTC KDM4E 1204/4885GMNN 908/4885LMNA 2628/4885
US-20090036309-A1 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use HCCS, VHL, OXA1L KDM4E 860/4885GMNN 655/4885LMNA 2379/4885
US-20170369503-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE HCCS, OXA1L, OTC KDM4E 1204/4885GMNN 908/4885LMNA 2628/4885
US-10023587-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use HCCS, OXA1L, OTC KDM4E 1204/4885GMNN 908/4885LMNA 2628/4885
US-20090275651-A1 Alcanoic Acid Amides Substituted by Saturated O-Heterocycles REN, AGTR1, ACE KDM4E 3074/4885GMNN 4377/4885LMNA 2865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.